logo
logo
AI Products 

The Human Recombinant Insulin Market is driven by increasing prevalence of diabetes

avatar
naufan003
The Human Recombinant Insulin Market is driven by increasing prevalence of diabetes

The human recombinant insulin market comprises insulin products that are produced through recombinant DNA technology. Recombinant human insulin is an artificially-made insulin that is identical to natural insulin produced by the human body. It is widely used for the treatment of diabetes and is affordable and easily available. The production of recombinant human insulin involves insertion of the human insulin gene into either yeast cells or E. coli bacteria which then produces insulin identical to natural insulin. Recombinant insulin provides several advantages over animal-derived insulin such as low risk of allergic reactions, high purity and consistency in dosage. Moreover, it is unaffected by food or exercise and has a smooth response curve.

The global recombinant human insulin market is estimated to be valued at US$ 47926.32 Bn in 2024 and is expected to exhibit a CAGR of 12% over the forecast period 2024 to 2030.

Key Takeaways

Key players operating in the human recombinant insulin market are Au Optronics Corp., Blue Spark Technologies, Cymbet Corporation, E Ink Holdings Inc., Enfucell Softbattery, Imprint Energy Inc., LG Electronics, and Palo Alto Research Center Incorporated. Key players focus on developing innovative diabetes management solutions through initiatives like collaborations and new product launches.

The growing prevalence of diabetes across the world is a major factor driving the demand for recombinant human insulin. According to International Diabetes Federation, over 537 million adults were living with diabetes in 2021 worldwide and the number is expected to rise to 643 million by 2030 and 783 million by 2045. Rapid urbanization, sedentary lifestyles and obesity are contributing significantly to the growing diabetes burden.

Recombinant human insulin manufacturers are focusing on expanding their geographic presence globally especially in emerging regions of Asia Pacific, Latin America, Middle East and Africa. This is due to increased diagnosis rates, growing health awareness and enhanced access to healthcare in these regions. Market players are investing in capacity expansions, local manufacturing and collaborations with regional distributors to better cater to the regional demand.

Market Drivers

The increasing prevalence of diabetes is a major driver of The Recombinant Human Insulin Market. As per International Diabetes Federation, over 537 million adults were living with diabetes globally in 2021 and the number is projected to touch 643 million cases by 2030, indicating significant increase in patient pool needing treatment. Other key drivers include growing geriatric population who are at higher risk of diabetes, lifestyle changes leading to rise in obesity and rapid urbanization in developing nations promoting sedentary habits. Moreover, advantages of recombinant human insulin over animal-derived insulin such as consistent strength, predictable absorption and decreased risk of allergic reactions are boosting its adoption rate.

Impact of geopolitical situation on Human Recombinant Insulin Market growth

The current geopolitical instability across many parts of the world is impacting the growth of the human recombinant insulin market. The ongoing Russia-Ukraine war has disrupted supply chains and exports of key raw materials needed to manufacture recombinant insulin. This has increased input costs for companies. Heightened economic uncertainties and rising inflation caused by the war are weakening global healthcare spending growth rates. Many diabetes patients in affected European countries are facing difficulties in affording and accessing insulin therapy. The political instability and economic distress in Latin American and Middle Eastern countries are also slowing market demand growth in these regions.

To sustain growth, companies must diversify their sourcing networks and establish alternate supply routes that avoid conflict zones as much as possible. Developing strategic tie-ups with local players can help establish manufacturing facilities in more politically stable markets to service regional needs. Companies must invest in innovative storage and distribution technologies that can withstand supply chain disruptions. They should work with governments to make insulin therapies more affordable through subsidies, pricing controls etc. New formulations with less frequent dosing can help solve affordability issues.

Geographical regions where market concentrated in terms of value

The human recombinant insulin market in terms of value is highly concentrated in few developed regions of North America and Western Europe. This is because these regions have high per capita healthcare spends and a large diabetic patient base opting for expensive recombinant insulin products. According to estimates, the United States alone accounts for over 35% of global market revenues currently due to its massive pharmaceutical industry and uptake of new therapies. Other major value shares are held by developed markets of Western Europe like Germany, France and the UK. However, these shares may decline slowly as the market expands into emerging Asian and Latin American countries in future due to growing disease burdens and incomes in those regions.

Fastest growing region for Human Recombinant Insulin market

The Asia Pacific region excluding Japan is projected to be the fastest growing market for human recombinant insulin during the forecast period due to several factors. Firstly, the prevalence of diabetes is surging in heavily populated Asia Pacific countries like China and India primarily due to rapid economic growth, urbanization and lifestyle changes leading to obesity. Secondly, improving access to healthcare insurance and increasing spending power is enhancing the affordability of insulin therapies. Local production of low-cost recombinant insulin products through partnerships and technology transfers is boosting clinical usage. Favorable regulatory frameworks encouraging the development of cutting-edge innovations are attracting larger investments from leading players to tap the high-growth potential. These factors are expected to significantly raise demand and drive the Asia Pacific excluding Japan market at an accelerated pace over the next decade.


Get more insights on this topic: https://www.newsstatix.com/human-recombinant-insulin-market-share/

collect
0
avatar
naufan003
guide
Zupyak is the world’s largest content marketing community, with over 400 000 members and 3 million articles. Explore and get your content discovered.
Read more